SG11201903462UA - Methods of delivering a neuroprotective polypeptide to the central nervous system - Google Patents

Methods of delivering a neuroprotective polypeptide to the central nervous system

Info

Publication number
SG11201903462UA
SG11201903462UA SG11201903462UA SG11201903462UA SG11201903462UA SG 11201903462U A SG11201903462U A SG 11201903462UA SG 11201903462U A SG11201903462U A SG 11201903462UA SG 11201903462U A SG11201903462U A SG 11201903462UA SG 11201903462U A SG11201903462U A SG 11201903462UA
Authority
SG
Singapore
Prior art keywords
neuroprotective polypeptide
international
neuroprotective
subject
cns
Prior art date
Application number
SG11201903462UA
Inventor
Dong Kim
Hee Kim
Nigel Greig
Original Assignee
Peptron Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptron Inc, Us Health filed Critical Peptron Inc
Publication of SG11201903462UA publication Critical patent/SG11201903462UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14212—Pumping with an aspiration and an expulsion action
    • A61M5/14228—Pumping with an aspiration and an expulsion action with linear peristaltic action, i.e. comprising at least three pressurising members or a helical member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111 011101010111110111110101111111111111011111011111011111110111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/075901 Al 26 April 2018 (26.04.2018) WIP0 I PCT (51) International Patent Classification: Transfer, 6011 Executive Blvd. Suite 325, Rockville, MD A61K 38/26 (2006.01) A61K 9/16 (2006.01) 20852 (US). A61K 47/34 (2017.01) A61P 25/28 (2006.01) (72) Inventors: KIM, Dong, Seok; 10000 Town Center (21) International Application Number: Ave., Apt. 413, Columbia, MD 21044 (US). KIM, Hee, PCT/US2017/057606 Kyung; 108-706, 501, Expo-ro, Yuseong-gu, Daejeon (22) International Filing Date: (KR). GREIG, Nigel, H.; 11 Anne Brent Garth, Phoenix, MD 21131 (US). 20 October 2017 (20.10.2017) (25) Filing Language: English (74) Agent: ZERHUSEN, Bryan, D. et al.; Locke Lord LLP, P.O. Box 55874, Boston, MA 02205 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/410,748 20 October 2016 (20.10.2016) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicants: PEPTRON, INC. [KR/KR]; 37-24, Yuseong- DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, daero, 1628 Beon-gil, Yuseong-gu, Daejeon, 305-811 (KR). HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, THE UNITED STATES OF AMERICA, as represented KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, by THE SECRETARY, DEPARTMENT OF HELATH MG, MK, MN, MW, MX, MY MZ, NA, NG, NI, NO, NZ, & HUMAN SERVICES [US/US]; Office of Technology Title: METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM (54) = FIG. 1A = b.0 3 = R ,. a a = Li c o I-) a 2 1 x ,,, W 0 I -,-- = _ = _ _= — = = - _ 0 7 14 21 Time (day) = : The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central (57) _ nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically 1-1 , 1 effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, 11 or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at CT least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained in release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) IN of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed 0 --.... is Ot in 11 a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject need thereof. 0 ei O [Continued on next page] WO 2018/075901 Al MIDEDIMOMOIDEIREEMOMMIMOIMMENVOIMIE OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201903462UA 2016-10-20 2017-10-20 Methods of delivering a neuroprotective polypeptide to the central nervous system SG11201903462UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410748P 2016-10-20 2016-10-20
PCT/US2017/057606 WO2018075901A1 (en) 2016-10-20 2017-10-20 Methods of delivering a neuroprotective polypeptide to the central nervous system

Publications (1)

Publication Number Publication Date
SG11201903462UA true SG11201903462UA (en) 2019-05-30

Family

ID=60382598

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903462UA SG11201903462UA (en) 2016-10-20 2017-10-20 Methods of delivering a neuroprotective polypeptide to the central nervous system

Country Status (12)

Country Link
US (2) US11273130B2 (en)
EP (1) EP3528836A1 (en)
JP (2) JP2020500163A (en)
KR (2) KR20190086460A (en)
CN (1) CN110191717A (en)
AU (1) AU2017345724B2 (en)
BR (1) BR112019008021A2 (en)
CA (1) CA3040906A1 (en)
MX (1) MX2019004476A (en)
SG (1) SG11201903462UA (en)
WO (1) WO2018075901A1 (en)
ZA (1) ZA201902486B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3528836A1 (en) 2016-10-20 2019-08-28 Peptron, Inc. Methods of delivering a neuroprotective polypeptide to the central nervous system
BR112022001595A2 (en) * 2019-07-29 2022-03-22 Peptron Inc Pharmaceutical composition for treating or inhibiting the progression of levodopa-induced dyskinesia
CN116600829A (en) * 2020-05-22 2023-08-15 波士顿大学董事会 Methods and compositions for treating fibrotic diseases
CN112014193B (en) * 2020-07-24 2021-06-15 武汉大学中南医院 Novel FJ dyeing method and device
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN116392576A (en) * 2023-05-26 2023-07-07 南通大学 Application of GIP receptor agonist in preparation of drugs for treating spinal cord injury repair targets

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
PT1238659E (en) 1996-02-02 2005-01-31 Alza Corp SUSTAINED LIBERATION OF AN ACTIVE AGENT USING AN IMPLANTABLE SYSTEM
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
WO1999007404A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
ATE383867T1 (en) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc NOVEL EXENDIN AGONISTS
PT1041975E (en) 1997-12-22 2003-01-31 Alza Corp RATE CONTROL MEMBERS FOR CONTROLLED DRUG SUPPLY DEVICES
JP4173635B2 (en) 1997-12-29 2008-10-29 インターシア セラピューティクス，インコーポレイティド Permeation supply apparatus having membrane plug holding mechanism
ES2378675T3 (en) 1997-12-30 2012-04-16 Intarcia Therapeutics, Inc Delivery system of a beneficial agent with a sealing membrane
AU771132B2 (en) 1998-12-31 2004-03-11 Intarcia Therapeutics, Inc. Osmotic delivery system having space efficient piston
DE60023361T2 (en) 1999-12-21 2006-04-27 Alza Corp., Mountain View VALVE FOR OSMOTIC DEVICES
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
BR0312429A (en) 2002-06-26 2005-04-19 Alza Corp Minimal and volume efficient deformity piston for osmosis drug delivery systems
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
CN100548411C (en) 2003-03-31 2009-10-14 精达制药公司 Be provided with the osmotic pumps of internal pressure releasing parts
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
KR101106510B1 (en) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 Two-piece, internal-channel osmotic delivery system flow modulator
DK2049081T3 (en) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotic delivery systems and piston arrangements
KR100805208B1 (en) * 2007-03-27 2008-02-21 주식회사 펩트론 Composition and microsphere for controlled-release of exendin and method of preparing the same
ES2402172T3 (en) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Suspension formulation of insulinotropic peptides and uses thereof
CN107638562B (en) 2009-09-28 2022-12-02 精达制药公司 Rapid establishment and/or termination of substantial steady-state drug delivery
US9259432B1 (en) * 2011-01-31 2016-02-16 Parminder J. S. Vig Composition and methods for targeted delivery of a therapeutic compound to the brain or spinal cord of a subject for treatment of neurodegenerative diseases
JP2014520159A (en) * 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Method for treating diabetes with sustained-release preparation of GLP-1 receptor agonist
ITMI20130325A1 (en) 2013-03-05 2014-09-06 Telecom Italia Spa METHOD OF MEASURING AND MONITORING THE LEVEL OF ACCESS TO PERSONAL DATA GENERATED BY RESOURCES OF A USER DEVICE
JP2015192425A (en) 2014-03-28 2015-11-02 富士通株式会社 Demand accommodation change order determination method and demand accommodation change order determination program
WO2015158270A1 (en) * 2014-04-16 2015-10-22 山东绿叶制药有限公司 Exenatide-containing composition and preparation method therefor
EP3528836A1 (en) 2016-10-20 2019-08-28 Peptron, Inc. Methods of delivering a neuroprotective polypeptide to the central nervous system

Also Published As

Publication number Publication date
US20200046645A1 (en) 2020-02-13
MX2019004476A (en) 2019-09-23
KR20190086460A (en) 2019-07-22
AU2017345724A1 (en) 2019-06-06
CN110191717A (en) 2019-08-30
WO2018075901A8 (en) 2019-05-23
CA3040906A1 (en) 2018-04-26
US20220265563A1 (en) 2022-08-25
RU2019115110A3 (en) 2021-03-02
EP3528836A1 (en) 2019-08-28
KR20210092335A (en) 2021-07-23
ZA201902486B (en) 2021-01-27
AU2017345724B2 (en) 2024-04-18
BR112019008021A2 (en) 2019-07-09
WO2018075901A1 (en) 2018-04-26
WO2018075901A9 (en) 2018-06-07
JP2020500163A (en) 2020-01-09
US11273130B2 (en) 2022-03-15
US11771657B2 (en) 2023-10-03
RU2019115110A (en) 2020-11-24
JP2023065401A (en) 2023-05-12

Similar Documents

Publication Publication Date Title
SG11201903462UA (en) Methods of delivering a neuroprotective polypeptide to the central nervous system
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908391XA (en) Methods for modulating an immune response
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201805579SA (en) Recombinant igg fc multimers
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof